CTRI/2020/05/025286招募中未知
A randomized, double-blind, placebo controlled clinical study to evaluate the efficacy and safety of the formulation for vitality, vigour, sexual well-being and improvement in quality of life in ageing males.
Sami Labs Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Married male subjects of age ranging from 35-60 years with both years inclusive (minimum age being 35 years and maximum age being 60 years).
- •2 Complaints with symptoms of fatigue and diminished vitality with AMS questionnaire score >=27 and <= 42.
- •3 Self-reported Mild to moderate Erectile problems with IIEF-5 score >=12 and <= 21 with difficulty in maintaining erection or premature ejaculation.
- •4 The subjects must be in a marital relationship (Married), having stable monogamous sexual relationship with a female for a minimum of last 06 months and continue throughout till the end of the study.
- •5 Physically active and Planning to have regular sexual activity.
- •6 Commitment to comply with study protocol requirements.
- •7 Willing to sign informed consent.
排除标准
- •1 History of smoking, alcohol intake and narcotic/drug abuse within 3 months before Screening.
- •2 Subjects who want to lose weight or looking for weight loss program or significant lifestyle related modifications during the study.
- •3 History of surgical interventions or subjects with major psychiatric and neurological disorders such as Schizophrenia,Mental disorders, Alzheimerâ??s, Parkinsonism and Epilepsy, Multiple sclerosis etc.), major trauma or infections that are associated with the development of symptoms of ED and considered a potential cause of ED, severe systemic disorders including blood diseases and leukemias.
- •4 Having genital abnormalities or anatomical deformity of the penis including severe penile fibrosis or Peyronies disease or phimosis or any other condition which prevents normal sexual intercourse.
- •5 With blood pressure more than or equal to 140/85 mmHg and those who were on a â??chronic useâ?? for a minimum of 12 months or more of the following class of drugs viz Diuretics, Beta blockers and Calcium channel blockers.Subjects with blood pressure less than 140/85 and on monotherapy or low dose combination therapy without change in the dose from past 06 months need not be excluded.
- •6 Subjects with HbA1c >= 6.5.
- •7 Subjects with history of clinically significant thyroid disorder (hypo or hyper), gastrointestinal, cardiovascular, haematological, hepatic (SGOT or SGPT levels > 2 times Upper Limit of Normal),renal (serum creatinine >= 1.3 mg/dl),dialysis,respiratory or genitourinary abnormalities or diseases.
- •8 BMI > 30 Kg/m2.
- •9 Subjects detected with HIV and suffering from AIDS or on antiviral or anti-retroviral therapy.
- •10 Subjects with any clinically significant laboratory or ECG findings during screening.
- •11 Those subjects with Premature Ejaculation and organic impotence and clinically defined prostatitis and who have undergone pelvic surgery.
- •12 Subjects who are taking medications for erectile dysfunction, Phosphodiesterase Type-5 Inhibitors including sildenafil, tadalafil, vardenafil, avanafil must stop using these medications for at least 04 weeks before baseline visit.
- •13 Subjects those are not willing to stop taking the vitamins and supplements including herbal during the course of the study.
- •14 Subject who are allergic to herbal supplements and medications.
- •15 Subjects continuing tricyclic antidepressant and atypical antipsychotic drugs for the last 03 months.
- •16 Subject having participated in any clinical trial within last 03 months or any trial for testosterone boosting or ED,vigour,vitality, male sexual health and performance trials.
- •17 Subjects not ready to provide the identification proof i.e. Age and Gender,not ready to sign the consent and unable to comply with the protocol.
研究者
相似试验
招募中
不适用
To evaluate efficacy of Cyperus rotundus containing Stilbenes for weight management in obese individuals.CTRI/2022/09/045790Sami Sabinsa Group Limited
已完成
不适用
A clinical study to assess effect of an herbal product in improving testosterone levels in healthy young malesCTRI/2018/11/016337aila Nutraceuticals120
已完成
不适用
Effect of LN22197 in healthy subjects with sleep disturbance due to mild to moderate musculoskeletal discomfortCTRI/2022/09/045855aila Nutraceuticals60
已完成
不适用
Clinical trial to evaluate the efficacy and safety of investigational product (MXP22) on liver health.CTRI/2022/06/043558Synergia Life Sciences Pvt Ltd59
进行中（未招募）
不适用
A clinical study to evaluate the safety and efficacy of a food supplement in improving skin healthCTRI/2022/11/047326aturetech Co., Ltd.